{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-014184","form_type":"8-K","ticker":"MTVA","cik":"0001638287","company_name":"MetaVia Inc.","filed_at":"2024-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.064077+00:00","generated_at":"2026-05-30T06:08:03.150493+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NeuroBo completes Phase 2a MASH trial dosing; topline data due December 2024","bullets":["Last patient last visit in two-part Phase 2a trial of DA-1241, a GPR119 agonist for MASH.","95 of 109 randomized patients completed dosing across Part 1 (DA-1241 vs placebo) and Part 2 (DA-1241 + sitagliptin vs placebo).","Primary endpoint: change from baseline in ALT at Week 16; secondary endpoints include lipid and safety measures.","Topline data from both parts expected in December 2024; prior Phase 1 showed DA-1241 well tolerated."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-014184","json":"https://secwatch.observer/filing/0001558370-24-014184.json","markdown":"https://secwatch.observer/filing/0001558370-24-014184.md","text":"https://secwatch.observer/filing/0001558370-24-014184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024014184/0001558370-24-014184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1638287/000155837024014184/nrbo-20241104x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T06:08:03.150493+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}